520 results
Page 5 of 26
8-K
EX-99.1
ekk8febyj7frvd
11 Jan 21
Regulation FD Disclosure
4:07pm
8-K
EX-99.1
82cdnij
14 Dec 20
Regulation FD Disclosure
8:04am
8-K
EX-99.2
kowpnpzxwznrrb2a o6s
14 Dec 20
Regulation FD Disclosure
8:04am
8-K
EX-99.1
olf2o 0pfzez9
17 Nov 20
Caladrius Biosciences Announces the Resignation of Dr. Douglas Losordo, Chief Medical Officer
4:06pm
8-K
EX-99.1
h32hyymxtsiei1
5 Nov 20
Caladrius Biosciences Provides Corporate Update and Reports 2020 Third Quarter Financial Results
4:09pm
8-K
EX-99.1
auzm3r8e5amcyyqy
13 Aug 20
Caladrius Biosciences Provides Corporate Update and Reports 2020 Second Quarter Financial Results
4:08pm
8-K
EX-10.1
s6pydf11k olcpa5q
10 Jul 20
Entry into a Material Definitive Agreement
4:41pm
8-K
EX-10.2
dx3a mwt5rgqh7
10 Jul 20
Entry into a Material Definitive Agreement
4:41pm
424B5
mhsdjiyui5ty dae
26 May 20
Prospectus supplement for primary offering
4:02pm
8-K
EX-10.1
5mihtquzrlyj
26 May 20
Caladrius Biosciences Announces $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
8:02am
8-K
EX-10.2
k8hly7
26 May 20
Caladrius Biosciences Announces $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
8:02am
8-K
EX-99.1
ech4 sxgi
26 May 20
Caladrius Biosciences Announces $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
8:02am
8-K
EX-99.1
rz9sohlmoow tr
7 May 20
Caladrius Biosciences Provides Corporate Update and Reports 2020 First Quarter Financial Results
4:09pm
424B5
o4d1o98anm0s8ag5x9g
27 Apr 20
Prospectus supplement for primary offering
7:30am
8-K
EX-10.1
899qzwdtl39f25ltieh
24 Apr 20
Caladrius Biosciences Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:02pm
8-K
EX-99.1
74x6xpk4g3xqe18g
24 Apr 20
Caladrius Biosciences Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:02pm
8-K
EX-10.2
0tn54w pfyoxzc13z8x1
24 Apr 20
Caladrius Biosciences Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:02pm
8-K
EX-99.1
b5bd5vqwfy
5 Mar 20
Caladrius Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
4:07pm